Literature DB >> 17314158

Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.

Cristina Villena1, Julia G Prado, Maria Carmen Puertas, Miguel Angel Martínez, Bonaventura Clotet, Lidia Ruiz, Neil T Parkin, Luis Menéndez-Arias, Javier Martinez-Picado.   

Abstract

Deletions, insertions, and amino acid substitutions in the beta3-beta4 hairpin loop-coding region of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) have been associated with resistance to nucleoside RT inhibitors when appearing in combination with other mutations in the RT-coding region. In this work, we have measured the in vivo fitness of HIV-1 variants containing a deletion of 3 nucleotides affecting codon 69 (Delta69) of the viral RT as well as the replication capacity (RC) ex vivo of a series of recombinant HIV-1 variants carrying an RT bearing the Delta69 deletion or the T69A mutation in a multidrug-resistant (MDR) sequence background, including the Q151M complex and substitutions M184V, K103N, Y181C, and G190A. Patient-derived viral clones having RTs with Delta69 together with S163I showed increased RCs under drug pressure. These data were consistent with the viral population dynamics observed in a long-term-treated HIV-1-infected patient. In the absence of drugs, viral clones containing T69A replicated more efficiently than those having Delta69, but only when patient-derived sequences corresponding to RT residues 248 to 527 were present. These effects could be attributed to a functional interaction between the C-terminal domain of the p66 subunit (RNase H domain) and the DNA polymerase domain of the RT. Finally, recombinant HIV-1 clones bearing RTs with MDR-associated mutations, including deletions at codon 69, showed increased susceptibilities to protease inhibitors in phenotypic assays. These effects correlated with impaired Gag cleavage and could be attributed to delayed maturation and decreased production of active protease in those variants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314158      PMCID: PMC1900151          DOI: 10.1128/JVI.02135-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors.

Authors:  B Masquelier; E Race; C Tamalet; D Descamps; J Izopet; C Buffet-Janvresse; A Ruffault; A S Mohammed; J Cottalorda; A Schmuck; V Calvez; E Dam; H Fleury; F Brun-Vézinet
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

Authors:  G Bleiber; M Munoz; A Ciuffi; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 3.  HIV chemotherapy.

Authors:  D D Richman
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

4.  Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine.

Authors:  K Suzuki; G R Kaufmann; M Mukaide; P Cunningham; C Harris; L Leas; M Kondo; M Imai; S L Pett; R Finlayson; J Zaunders; A Kelleher; D A Cooper
Journal:  AIDS Res Hum Retroviruses       Date:  2001-09-01       Impact factor: 2.205

5.  Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.

Authors:  T Imamichi; M A Murphy; H Imamichi; H C Lane
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors.

Authors:  M A Winters; K L Coolley; P Cheng; Y A Girard; H Hamdan; L C Kovari; T C Merigan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy.

Authors:  L Ross; M Johnson; R G Ferris; S A Short; L R Boone; T E Melby; R Lanier; M Shaefer; M St Clair
Journal:  J Hum Virol       Date:  2000 May-Jun

8.  Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

Authors:  T Imamichi; S C Berg; H Imamichi; J C Lopez; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.

Authors:  R E Jeeninga; W Keulen; C Boucher; R W Sanders; B Berkhout
Journal:  Virology       Date:  2001-05-10       Impact factor: 3.616

10.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Authors:  Martin S Hirsch; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Richard T D'Aquila; Lisa M Demeter; Scott M Hammer; Victoria A Johnson; Clive Loveday; John W Mellors; Donna M Jacobsen; Douglas D Richman
Journal:  Clin Infect Dis       Date:  2003-06-23       Impact factor: 9.079

View more
  13 in total

1.  Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.

Authors:  B Chaplin; G Eisen; J Idoko; D Onwujekwe; E Idigbe; I Adewole; W Gashau; S Meloni; A D Sarr; J L Sankalé; E Ekong; R L Murphy; P Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205

2.  Impaired replication capacity of acute/early viruses in persons who become HIV controllers.

Authors:  Toshiyuki Miura; Zabrina L Brumme; Mark A Brockman; Pamela Rosato; Jennifer Sela; Chanson J Brumme; Florencia Pereyra; Daniel E Kaufmann; Alicja Trocha; Brian L Block; Eric S Daar; Elizabeth Connick; Heiko Jessen; Anthony D Kelleher; Eric Rosenberg; Martin Markowitz; Kim Schafer; Florin Vaida; Aikichi Iwamoto; Susan Little; Bruce D Walker
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.

Authors:  Theodore D Ruel; Moses R Kamya; Pelin Li; William Pasutti; Edwin D Charlebois; Teri Liegler; Grant Dorsey; Philip J Rosenthal; Diane V Havlir; Joseph K Wong; Jane Achan
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

Review 4.  Antiretroviral therapy : optimal sequencing of therapy to avoid resistance.

Authors:  Jorge L Martinez-Cajas; Mark A Wainberg
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection.

Authors:  Anne Derache; Carole L Wallis; Saran Vardhanabhuti; John Bartlett; Nagalingeswaran Kumarasamy; David Katzenstein
Journal:  J Infect Dis       Date:  2015-07-14       Impact factor: 5.226

6.  Case report of the rare deletion at codon 69 of reverse transcriptase in a South African HIV-1 subtype C infected patient.

Authors:  Carole L Wallis; Willem D F Venter; Wendy S Stevens; Maria A Papathanasopoulos
Journal:  Virus Genes       Date:  2010-12       Impact factor: 2.332

7.  Selection and characterization of HIV-1 with a novel S68 deletion in reverse transcriptase.

Authors:  Raymond F Schinazi; Ivana Massud; Kimberly L Rapp; Meta Cristiano; Mervi A Detorio; Richard A Stanton; Matthew A Bennett; Monique Kierlin-Duncan; Johan Lennerstrand; James H Nettles
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

8.  Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.

Authors:  Judith Dalmau; Maria Carmen Puertas; Marta Azuara; Ana Mariño; Nicole Frahm; Beatriz Mothe; Nuria Izquierdo-Useros; Maria José Buzón; Roger Paredes; Lourdes Matas; Todd M Allen; Christian Brander; Carlos Rodrigo; Bonaventura Clotet; Javier Martinez-Picado
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

9.  Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.

Authors:  Maria Carmen Puertas; Maria Jose Buzón; Anna Artese; Stefano Alcaro; Luis Menendez-Arias; Carlo Federico Perno; Bonaventura Clotet; Francesca Ceccherini-Silberstein; Javier Martinez-Picado
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

10.  Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria.

Authors:  Claudia A Hawkins; Beth Chaplin; John Idoko; Ernest Ekong; Isaac Adewole; Wadzani Gashau; Robert L Murphy; Phyllis Kanki
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.